## Analysis of PCP in Advanced HIV ### Correct Statements (Options 0, 1, 2) **Key Point:** Trimethoprim-sulfamethoxazole (TMP-SMX) is the gold standard first-line treatment AND prophylaxis for PCP, and it simultaneously covers *Toxoplasma gondii* — a critical co-infection in CD4 <100 cells/μL. [cite:Harrison 21e Ch 197] **High-Yield:** The classic triad of PCP findings includes: - Elevated serum LDH (often >400 IU/L) - Hypoxemia (PaO₂ <70 mmHg on room air) - Normal or minimally abnormal CXR early in disease This dissociation between clinical severity and radiographic findings is pathognomonic. [cite:Harrison 21e Ch 197] **Key Point:** PCP prophylaxis is a CD4-count-driven intervention — initiated at <200 cells/μL, independent of symptoms or prior PCP history. This is a cornerstone of opportunistic infection prevention. [cite:Harrison 21e Ch 197] ### Why Option 3 Is Incorrect **Warning:** Cystic fibrosis (CF) is NOT a recognized risk factor for PCP. CF patients are susceptible to *Burkholderia cepacia*, *Pseudomonas aeruginosa*, and other respiratory pathogens — but NOT *Pneumocystis jirovecii*. PCP is fundamentally a disease of **CD4 lymphopenia** (HIV, hematologic malignancies, prolonged corticosteroid use, organ transplantation) — not structural lung disease. This is a classic distractor that conflates two unrelated respiratory conditions. ### Pathophysiology Summary | Feature | PCP in HIV | CF | | --- | --- | --- | | **Immune defect** | CD4 lymphopenia | Neutrophil dysfunction, mucus plugging | | **Organism** | *Pneumocystis jirovecii* | *Burkholderia*, *Pseudomonas*, fungi | | **CXR pattern** | Bilateral interstitial (or normal) | Bronchiectasis, bronchial wall thickening | | **CD4 threshold** | <200 cells/μL | Not applicable | [cite:Harrison 21e Ch 197]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.